Drug Testing for Sober Living & Recovery Residences

No minimum to open a wholesale account. The first wholesale tier kicks in at 100 units of a SKU, which most residences hit on their first monthly order. A 12-bed house testing each resident weekly is using ~50 cups a month — well above the first wholesale tier on a single-month order.

Most residences standardize on a 10-panel CLIA-waived dip card as the workhorse — it covers the standard SAMHSA-5 plus benzodiazepines, methadone, oxycodone, MDMA, and barbiturates at the most affordable per-cup cost. Residences serious about fentanyl awareness move to the 13-panel cup that adds fentanyl on the same SKU. The 5-panel is the most basic option for residences with the tightest budgets.

For most residences, yes. Fentanyl-driven overdose mortality is now the leading cause of death for many residents who relapse. Fentanyl does not cross-react with the standard opiate immunoassay, so a panel without dedicated fentanyl screening will miss most fentanyl exposure. Our 13-panel cup adds fentanyl on the same SKU as the standard panel. Many residences also stock fentanyl single-strip tests for harm-reduction conversations with residents.

Yes — our cups support both observed and unobserved collection. Most residences use unobserved collection as the default with specific criteria (after an aberrant result, for residents in their first 30 days, when there is reason to believe the resident may attempt to alter the specimen) for moving to observed collection. Built-in specimen-validity testing (creatinine, pH, oxidants) on our 12- and 14-panel cups provides a check on unobserved collections.

Yes — and we recommend it for network operators. Our wholesale account structure supports sub-account consumption tracking so each house gets its own ship-to address and consumption record, while a single invoice consolidates to the central operator. Wholesale tier is set against combined network volume, typically dramatically better than running each house as a separate small account.

That's a residence-policy decision rather than a supply question, but the typical NARR-aligned framework involves a defined response sequence specified in the residence agreement — initial conversation, increased testing frequency, treatment-engagement referral, and eventual discharge from the residence if abstinence cannot be re-established. The residence agreement should specify the procedure clearly, and the response should align with state landlord-tenant law and FHA reasonable-accommodation requirements. Single-incident immediate-eviction policies can be legally exposed.

Yes — once your wholesale account is approved, you can set up a recurring monthly order at the residence's historical volume with an additional 5-10% off our wholesale pricing. For house managers and residence operators, monthly subscriptions eliminate the reorder cycle entirely. You can pause, skip, or change quantities from the account dashboard.

No. Recovery residences run drug testing as a contractual abstinence-verification program under the resident agreement, not as clinical drug monitoring. You do not need a CLIA Certificate of Waiver to run these cups for abstinence-verification purposes in a recovery-residence setting (CLIA applies to testing performed for clinical decision-making by or on behalf of a healthcare provider). Residences that are part of an integrated clinical program should consult their clinical program's compliance team on CLIA applicability.